Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Adagrasib |
Trade Name | Krazati |
Synonyms | MRTX849|MRTX-849|MRTX 849 |
Drug Descriptions |
Krazati (adagrasib) covalently binds to and stabilizes GDP-bound KRAS G12C, thereby preventing KRAS downstream signaling and potentially inhibiting tumor growth (PMID: 31658955). Krazati (adagrasib) is FDA-approved for use in patients with locally advanced or metastatic non-small cell lung cancer harboring KRAS G12C who have received one or more prior therapy, and in combination with Erbitux (cetuximab) for patients with advanced or metastatic colorectal cancer harboring KRAS G12C (FDA.gov). |
DrugClasses | KRAS G12C inhibitor 34 |
CAS Registry Number | 2326521-71-3 |
NCIT ID | C157493 |